Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment o… Read more
Janux Therapeutics Inc (JANX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.013x
Based on the latest financial reports, Janux Therapeutics Inc (JANX) has a cash flow conversion efficiency ratio of -0.013x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.86 Million) by net assets ($976.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Janux Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Janux Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Janux Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Janux Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HeNan Splendor Science & Technology Co Ltd
SHE:002296
|
0.020x |
|
Merry Electronics Co Ltd
TW:2439
|
-0.111x |
|
CIMC Enric Holdings Limited
PINK:CIMEF
|
0.141x |
|
Farmers & Merchants Bancorp
OTCQX:FMCB
|
0.046x |
|
Timah Persero Tbk
JK:TINS
|
-0.113x |
|
Hunan Yussen Energy Technology
SHE:002986
|
-0.020x |
|
ODDITY Tech Ltd. Class A Ordinary Shares
NASDAQ:ODD
|
-0.023x |
|
Shandong Denghai Seeds Co Ltd
SHE:002041
|
0.070x |
Annual Cash Flow Conversion Efficiency for Janux Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Janux Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.02 Billion | $-43.81 Million | -0.043x | +70.83% |
| 2023-12-31 | $344.35 Million | $-50.58 Million | -0.147x | -9.75% |
| 2022-12-31 | $320.74 Million | $-42.92 Million | -0.134x | -188.78% |
| 2021-12-31 | $366.33 Million | $-16.98 Million | -0.046x | -115.53% |
| 2020-12-31 | $-14.64 Million | $-4.37 Million | 0.298x | -38.06% |
| 2019-12-31 | $-7.94 Million | $-3.83 Million | 0.482x | -- |